Crossref


1. The effect of nigella sativa supplementation on cardiometabolic outcomes in patients with non-alcoholic fatty liver: A randomized double-blind, placebo-controlled trial

- Mohammad Rashidmayvan

- Sarvenaz Vandyousefi

- Meisam Barati

- Shekoufeh Salamat

- Sara Ghodrat

- Maryam Khorasanchi

- Alireza Jahan-Mihan

- Elyas Nattagh-Eshtivani

- Majid Mohammadshahi

3. Prevalence and clinical characteristics of concurrent chronic hepatitis B and fatty liver disease in China: a systematic review and meta-analysis

- Jiayi Huang

- Sujuan Zhou

- Chengnan Guo

- Xin Zhang

- Shuzhen Zhao

- Luojia Dai

- Zhenqiu Liu

- Tiejun Zhang

6. Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis

- Ehsan Amini-Salehi

- Soheil Hassanipour

- Farahnaz Joukar

- Amir Ali Daryagasht

- Mohammad-Javad Khosousi

- Maryam Sadat Aleali

- Malek Moien Ansar

- Forough Heidarzad

- Elham Abdzadeh

- Azin Vakilpour

- Fariborz Mansour-Ghanaei

7. Prevalence of non-alcoholic fatty liver and its related factors in Iran: Systematic review and meta-analysis

- Maryam Chegeni

- Sairan Nili

- Mehdi Darabi

- Elham Gheysvandi

- Razieh Zahedi

- Elham Sharifian

- Hamid Reza Shoraka

- Mohammad Rostamkhani

- Leili Abedi Gheshlaghi

8. Fibroblast Growth Factor 21: A More Effective Biomarker Than Free Fatty Acids and Other Insulin Sensitivity Measures for Predicting Non-alcoholic Fatty Liver Disease in Saudi Arabian Type 2 Diabetes Patients

- Suhad Bahijri

- Basmah Eldakhakhny

- Sumia Enani

- Ghada Ajabnoor

- Alaa S Al-Mowallad

- Lubna Alsheikh

- Amani Alhozali

- Aliaa A Alamoudi

- Anwar Borai

- Jaakko Tuomilehto